RT Journal Article
SR Electronic
T1 Clinical Benefits and Budget Impact of Lenzilumab plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with COVID-19 in the United States from the Hospital Perspective
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.06.21264651
DO 10.1101/2021.10.06.21264651
A1 Adrian Kilcoyne
A1 Edward Jordan
A1 Allen Zhou
A1 Kimberly Thomas
A1 Alicia N. Pepper
A1 Dale Chappell
A1 Miyuru Amarapala
A1 Avery Hughes
A1 Melissa Thompson
YR 2021
UL http://medrxiv.org/content/early/2021/10/10/2021.10.06.21264651.abstract
AB Aims The study estimated the clinical benefits and budget impact of lenzilumab plus standard of care (SOC) compared with SOC alone in the treatment of hospitalized COVID-19 patients from the United States hospital perspective.Materials and Methods An economic model was developed to estimate the clinical benefits and costs for an average newly hospitalized COVID-19 patient, with a 28-day time horizon for the index hospitalization. Clinical outcomes from the LIVE-AIR trial included failure to achieve survival without ventilation (SWOV), mortality, time to recovery, intensive care unit (ICU) admission, and invasive mechanical ventilation (IMV) use. Base case costs included drug acquisition and administration for lenzilumab and hospital resource costs based on the level of care required. The inclusion of 1-year rehospitalization costs was examined in a scenario analysis.Results In the base case and all scenarios, treatment with lenzilumab plus SOC improved all specified clinical outcomes over SOC alone. Adding lenzilumab to SOC was also estimated to result in cost savings of $3,190 per patient in a population aged <85 years with CRP <150 mg/L and receiving remdesivir (base case). Per-patient cost savings were also estimated in the following scenarios: 1) aged <85 years with CRP <150 mg/L, with or without remdesivir ($1,858); 2) Black and African American patients with CRP <150 mg/L ($13,154); and 3) Black and African American patients from the full population ($2,763). In the full mITT population, a budget impact of $4,952 was estimated. When adding rehospitalization costs to the index hospitalization, a total per-patient cost savings of $5,154 was estimated.Conclusions The results highlight the clinical benefits for SWOV, ventilator use, time to recovery, mortality, time in ICU, and time on IMV, in addition to a favorable budget impact from the United States hospital perspective associated with adding lenzilumab to SOC for patients with COVID-19 pneumonia.Competing Interest StatementAK, EJ, DC, MA are employees of Humanigen Inc. AZ, KT, ANP, AH, MT are employees of EVERSANA which received funding from Humanigen Inc. to conduct this study.Clinical TrialNCT04351152Funding StatementThis work was supported by Humanigen Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current budget impact model was based on the The LIVE-AIR trial. Central IRB (ADVARRA) approval was obtained in addition to local IRB approval at each participating institution as appropriate for all aspects of this company-sponsored phase 3 clinical trial. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSome of the efficacy data used to inform the budget impact model was sourced from the Temesgen et al. (2021) publication (attached). Additional efficacy data are not publicly available at this time. https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1